The focus of my research is make tumor immunotherapy more effective and competent. Allogeneic hematopoietic stem cell transplantation (AHSCT) in combination with donor lymphocyte infusion has been a very effective therapy option for a variety of cancers. However, its use has to some extent been limited by graft-versus-host disease (GVHD), delayed immunological reconstitution and the rarity of suitable donors. Recent studies indicate that precursor T cells have a huge potential as suitable immunotherapeutic agents. The precursor T cells are generated in vitro from hematopoietic stem cells co-cultured with NOTCH expression systems. The resultant cells have antitumor properties, do not cause GVHD, enhances T cell reconstitution and can be used as an off-the shelf cellular therapy. Furthermore, they can be genetically manipulated to enhance their anti-tumor properties. My present research involves exploring the potentials of precursor T cells. In addition, I am presently designing protocols that can be used to manufacture human precursor T cells for use in clinical settings.